InvestorsHub Logo
Followers 12
Posts 1060
Boards Moderated 0
Alias Born 06/29/2017

Re: None

Friday, 03/01/2019 1:11:15 AM

Friday, March 01, 2019 1:11:15 AM

Post# of 6033
"The preliminary data from our Cohort B is increasingly relevant and potentially exciting as it suggests that the addition of HS-110 to nivolumab may restore anti-tumor activity in patients whose disease has progressed after treatment with a CPI."

https://www.heatbio.com/news-media/news-releases/detail/624/heat-biologics-presents-interim-phase-2-lung-cancer-data-on
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NHWK News